October, 2014 – Epidarex is a specialist life science venture capital group that recently raised a new fund of £47.5 million dedicated to UK start ups and university spin outs. Backers include US drug giant Eli Lilly, the Universities of Edinburgh, Glasgow and Aberdeen, King’s College London, the European Investment Fund, Scottish Enterprise and Strathclyde Pension fund.
Sinclair Dunlop is the fund’s managing partner, and he talks to us of his ambition for the fund to become a catalyst for the sector, ultimately helping to bridge the early-stage funding gap while demonstrating a competitive rate of return can be made for investors in this sector.